

#7
GNVPN.019BUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re the Application of) Group Art Unit: 1632
)
James M. Wilson et al.) Examiner: J. Martin
)
Appln. No. 09/242,977)
)
Filed: February 26, 1999)
)
For: METHOD FOR RECOMBINANT) May 5, 2000
ADENO-ASSOCIATED VIRUS)
DIRECTED GENE-THERAPY)
)
)
)

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO-1449 document listing and this paper pursuant to 37 CFR §1.56 and § 1.97-1.98. Form PTO-1449 is attached and copies of the references are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application, but before the receipt of a first Office Action on the merits. Therefore, no fees or declarations are necessary. The Commissioner is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

REMARKS

Document (AAB) is a U.S. Patent corresponding to PCT Patent Application No. WO 95/14771, which was submitted in the April 30, 1999 Information Disclosure Statement as document (AAL).

RECEIVED


TECH CENTER 1000/2000

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO-1449 during the course of the examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By



Cathy A. Kodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200